Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma
Introduction: The Evolving Landscape of High-Risk Neuroblastoma
High-risk neuroblastoma (HR-NBL) continues to represent one of the most significant challenges in pediatric oncology, accounting for approximately 15% of all pediatric cancer deaths. Despite intensive multimodal therapy—including induction chemotherapy, surgical resection, high-dose chemotherapy with autologous stem cell rescue, and radiotherapy—long-term survival rates historically remained below 50%. The emergence of immunotherapy targeting the disialoganglioside GD2, which is nearly universally expressed on neuroblastoma cells, has fundamentally shifted the therapeutic paradigm. Among these agents, dinutuximab beta, a chimeric monoclonal antibody, has emerged as a critical component in both the consolidation and relapsed settings. Recent data from the ITCC-SIOPEN BEACON Immuno and HR-NBL1/SIOPEN trials provide definitive evidence for the clinical application of this agent, clarifying its synergy with chemotherapy and its optimal administration without adjuvant cytokines.
The BEACON Immuno Trial: Addressing Relapsed and Refractory Disease
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.